# Photronics Inc: Form 10-Q for the period ended Jul 30, 2017

- Company: [Photronics Inc](/companies/plab.md) (CIK 810136)
- Form: 10-Q
- Filed: 2017-09-08
- Accepted by EDGAR: Sep 7, 2017, 18:01 ET
- Period: 2017-07-30
- Accession: 0001140361-17-034757
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/810136/000114036117034757/form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/810136/000114036117034757/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-07-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Gross profit | 3 months, 2017-05-01 to 2017-07-30 | $21.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-10-31 to 2017-07-30 | $64.9m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-05-01 to 2017-07-30 | $4.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-10-31 to 2017-07-30 | $12.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2017-05-01 to 2017-07-30 | $11.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-10-31 to 2017-07-30 | $33.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-05-01 to 2017-07-30 | $5.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-10-31 to 2017-07-30 | $19.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2017-05-01 to 2017-07-30 | $333.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2016-10-31 to 2017-07-30 | $2.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-05-01 to 2017-07-30 | $4.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-10-31 to 2017-07-30 | $7.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-05-01 to 2017-07-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-10-31 to 2017-07-30 | $0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-05-01 to 2017-07-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-10-31 to 2017-07-30 | $0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-05-01 to 2017-07-30 | 69,380,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-10-31 to 2017-07-30 | 69,311,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2016-10-31 to 2017-07-30 | $73.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-10-31 to 2017-07-30 | $38.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-07-30 | $340.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-07-30 | $468.6m | us-gaap:AssetsCurrent |
| Total assets | at 2017-07-30 | $1.01bn | us-gaap:Assets |
| Current liabilities | at 2017-07-30 | $79.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-07-30 | $153.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-07-30 | $739.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,966 characters.

### Overview

This management’s discussion and analysis (“MD&A”) of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes. Various segments of this MD&A contain forward-looking statements, all of which are presented based on current expectations, may be adversely affected by uncertainties and risk factors (presented throughout this filing and in our Annual Report on Form 10-K for the fiscal 2016 year) that may cause actual results to materially differ from these expectations.

We sell substantially all of our photomasks to semiconductor designers and manufacturers, and manufacturers of FPDs. Photomask technology is also being applied to the fabrication of other higher performance electronic products such as photonics, micro-electronic mechanical systems and certain nanotechnology applications. Thus, our selling cycle is tightly interwoven with the development and release of new semiconductor designs and flat panel applications, particularly as it relates to the semiconductor industry’s migration to more advanced design methodologies and fabrication processes. We believe that the demand for photomasks primarily depends on design activity, rather than sales volumes from products manufactured using photomask technologies. Consequently, an increase in semiconductor or FPD sales does not necessarily result in a corresponding increase in photomask sales. However, the reduced use of customized ICs, reductions in design complexity, other changes in the technology or methods of manufacturing or designing semiconductors, or a slowdown in the introduction of new semiconductor or FPD designs could reduce demand for photomasks – even if demand for semiconductors and FPDs increases. Advances in semiconductor, FPD and photomask design and semiconductor and FPD production methods could also reduce the demand for photomasks. Historically, the semiconductor industry has been volatile, with sharp periodic downturns and slowdowns. These downturns have been characterized by, among other things, diminished product demand, excess production capacity and accelerated erosion of selling prices.

Significant customer concentration is inherent in both our high-end IC and FPD businesses, as our largest FPD customer sometimes represents close to one-half of our FPD sales, and our largest IC customer can account for one-fourth of our IC sales. While this is beneficial to us when order levels from these large customers are high, it can present challenges when these customers’ short-term photomask demands slip, which can happen for a number of reasons. As is the case with other suppliers to the high-end semiconductor and display sectors, the concentration of our customers has increased through industry consolidation and attrition. The result of this customer concentration trend is that our sales are often subject to short-term volatility – particularly for high-end products. We believe our investments in China, which are discussed in Note 15 of our condensed consolidated financial statements, will serve to somewhat alleviate this volatility.

For merchant photomask companies, such as Photronics, there is an additional challenge, as more of our customers are employing captive photomask producing operations. This necessitates that we focus on areas that complement these captives in order for us to preserve our market share. Specifically, we endeavor to provide advanced technology photomasks and superior customer service, and thereby offer our customers a compelling alternative to expanding their captive photomask operations.

The global semiconductor industry, including mobile displays, is driven by end markets which have been closely tied to consumer driven applications of high performance semiconductor devices including, but not limited to, mobile communications and computing solutions. We are typically required to fulfill customer orders within a short period of time, sometimes within 24 hours. This results in us having a minimal level of backlog orders of, typically, one to two weeks. We cannot predict the timing of the industry’s transition to volume production of next-generation technology nodes or the timing of up and down cycles with precise accuracy, but believe that such transitions and cycles will continue into the future, beneficially and adversely affecting our business, financial condition and operating results as they occur. We believe our ability to remain successful in these environments is dependent upon achieving our goals of being a service and technology leader and efficient solutions supplier, which we believe should enable us to continually reinvest in our global infrastructure.

### Material Changes in Results of Operations

### Three and Nine Months ended July 30, 2017 and July 31, 2016

All of the following tabular comparisons, unless otherwise indicated, are for the three months ended July 30, 2017 (Q3-17) and July 31, 2016 (Q3-16), and for the nine months ended July 30, 2017 (YTD-17) and July 31, 2016 (YTD-16), in millions of dollars.

The following table represents selected operating information expressed as a percentage of net sales.

|  | Three Months Ended Q3-17 | Q3-16 | Nine Months Ended YTD-17 | YTD-16 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of sales | (80.5) | (74.5) | (80.3) | (73.9) |
| Gross margin | 19.5 | 25.5 | 19.7 | 26.1 |
| Selling, general and administrative expenses | (10.4) | (9.1) | (10.1) | (9.1) |
| Research and development expenses | (4.4) | (4.4) | (3.7) | (4.5) |
| Operating income | 4.7 | 12.0 | 5.9 | 12.5 |
| Other income (expense), net | (0.1) | 1.0 | (1.8) | (0.2) |
| Gain on sale of investment | - | 0.2 | - | 2.4 |
| Income before income tax provision | 4.6 | 13.2 | 4.1 | 14.7 |
| Income tax provision | (0.3) | (3.9) | (0.8) | (1.6) |
| Net income | 4.3 | 9.3 | 3.3 | 13.1 |
| Net (income) loss attributable to noncontrolling interests | (0.7) | (2.7) | (1.0) | (2.2) |
| Net income attributable to Photronics, Inc. shareholders | 3.6% | 6.6% | 2.3% | 10.9% |

### Net Sales

|  | Three Months Ended Q3-17 | Q3-16 | Percent Change | Nine Months Ended YTD-17 | YTD-16 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| IC | $85.1 | $91.7 | (7.1)% | $254.1 | $282.3 | (10.0)% |
| FPD | 26.5 | 31.5 | (16.2)% | 75.6 | 93.8 | (19.5)% |
| Total net sales | $111.6 | $123.2 | (9.4)% | $329.7 | $376.1 | (12.3)% |

Net sales for Q3-17 decreased 9.4% to $111.6 million as compared with $123.2 million for Q3-16. The decrease was primarily the result of lower high-end sales of both IC ($7.7 million) and FPD ($5.1 million) products. Revenues from mainstream IC products increased by $1.2 million, or 2.0%, while revenues were unchanged for mainstream FPD products. High-end photomask applications include mask sets for 45 nanometer and below for IC products, and G8 and above and active matrix organic light-emitting diode (AMOLED) display screen technologies for FPD products. Net sales for YTD-17 decreased by 12.3% to $329.7 million as a result of decreased high-end IC and FPD sales of $34.7 million and $20.0 million, respectively. The overall decline in sales of high-end products of 30.9% was partially offset by an increase in sales of mainstream products of $8.3 million, or 4.1%, of which approximately $6.6 million was attributable to IC photomasks.

Sales of high-end memory IC photomasks have increased sequentially, in each of the last three quarters, and we expect current sales levels to sustain, while high-end logic sales have been soft, as a large IC customer has experienced market share loss for some advanced nodes, and are not forecasted to recover until 2018. For the balance of 2017 and into 2018, we expect our markets to improve with the exception of high-end logic, where recovery is still a few quarters away. Our high-end memory business continues to grow and we anticipate continued volume growth in FPD, as we install more capacity. However, it may be another quarter or two before product mix turns more favorably towards high-end sales. We remain optimistic regarding our long-term growth expectation of all of our high-end markets, but see a slower recovery in high-end logic and high-end FPD, as their recoveries will be significantly dictated by the demands of our largest customers.

The following table presents changes in net sales from Q3-16 to Q3-17 and YTD-16 to YTD-17 by geographic area:

|  | Q3-16 to Q3-17 Net Sales in Q3-17 | Increase (Decrease) | Percent Change | YTD-16 to YTD-17 Net Sales in YTD-17 | Increase (Decrease) | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Taiwan | $44.0 | $(7.9) | (15.3)% | $132.7 | $(14.7) | (10.0)% |
| Korea | 32.0 | (5.6) | (15.0)% | 93.2 | (16.0) | (14.7)% |
| United States | 26.0 | 1.3 | 5.3% | 75.6 | (17.5) | (18.8)% |
| Europe | 8.9 | 0.5 | 6.2% | 26.4 | 1.4 | 5.8% |
| Other | 0.7 | 0.1 | 24.5% | 1.8 | 0.4 | 27.6% |
|  | $111.6 | $(11.6) | (9.4)% | $329.7 | $(46.4) | (12.3)% |

### Gross Margin

|  | Three Months Ended Q3-17 | Q3-16 | Percent Change | Nine Months Ended YTD-17 | YTD-16 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross profit | $21.7 | $31.5 | (30.9)% | $64.9 | $98.2 | (33.9)% |
| Percentage of net sales | 19.5% | 25.5% |  | 19.7% | 26.1% |  |

Gross margin percentage decreased to 19.5% in Q3-17 from 25.5% in Q3-16, and to 19.7% in YTD-17 from 26.1% YTD-16. These decreases were primarily driven by lower high-end product sales and increased depreciation. We operate in a high fixed cost environment and, to the extent that our revenues and utilization increase or decrease, gross margin will generally be positively or negatively impacted.

7

### Selling, General and Administrative Expenses

|  | Three Months Ended Q3-17 | Q3-16 | Percent Change | Nine Months Ended YTD-17 | YTD-16 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative expenses | $11.6 | $11.2 | 4.3% | $33.4 | $34.4 | (2.9)% |
| Percentage of net sales | 10.4% | 9.1% |  | 10.1% | 9.1% |  |

Selling, general and administrative expenses increased 4.3% in Q3-17 from Q3-16, primarily as a result of increased professional service fees. Year to date, selling, general and administrative expenses decreased 2.9% compared to the prior period, primarily due to the release of doubtful accounts reserves.

### Research and Development

|  | Three Months Ended Q3-17 | Q3-16 | Percent Change | Nine Months Ended YTD-17 | YTD-16 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $4.8 | $5.5 | (12.0)% | $12.0 | $16.6 | (27.6)% |
| Percentage of net sales | 4.4% | 4.4% |  | 3.7% | 4.5% |  |

Research and development expenses decreased by $0.7 million to $4.8 million in Q3-17, as compared with $5.5 million in Q3-16 and by $4.6 million to $12.0 million in YTD-17 from $16.6 million in YTD-16. These decreases are primarily reflective of reductions in activity levels of our global efforts associated with developing high-end process technologies for advanced sub-wavelength reticles.

### Other Income (Expense), net

|  | Three Months Ended Q3-17 | Q3-16 | Nine Months Ended YTD-17 | YTD-16 |
| --- | ---: | ---: | ---: | ---: |
| Interest and other income (expense), net | $0.4 | $1.8 | $(4.2) | $1.9 |
| Interest expense | (0.5) | (0.6) | (1.6) | (2.7) |
| Gain on sale of investment | - | 0.2 | - | 8.9 |
| Other income (expense), net | $(0.1) | $1.4 | $(5.8) | $8.1 |

Interest and other income (expense), net decreased in Q3-17 from $1.8 million in Q3-16 to $0.4 million, primarily as a result of the recognition of a $1.2 million favorable settlement of a liability in Q3-16 that was related to a prior year’s acquisition. Interest and other income (expense), net decreased in YTD-17 to $(4.2) million, as compared with $1.9 million in YTD-16, as a result of less unfavorable foreign currency exchange losses and the aforementioned settlement of a liability related to a prior year’s acquisition.

In Q3-17, interest expense decreased by $0.1 million from Q3-16 as a result of a reduced level of outstanding debt. Interest expense decreased in YTD-17 to $(1.6) million, as compared with $(2.7) million in YTD-16, primarily as a result of the impact of the maturing of our 3.25% convertible debt on April 1, 2016.

In January 2016 the Company sold a minority interest investment in a foreign entity and realized a gain of $8.8 million. In May 2016 the Company sold its 49.99% interest in the MP Mask Joint Venture and realized a gain of $0.2 million.

### Income Tax Provision

|  | Three Months Ended Q3-17 | Q3-16 | Nine Months Ended YTD-17 | YTD-16 |
| --- | ---: | ---: | ---: | ---: |
| Income tax provision | $0.3 | $4.8 | $2.8 | $6.1 |
| Effective income tax rate | 6.5% | 29.4% | 20.7% | 11.1% |

Our effective income tax rate is sensitive to the jurisdictional mix of earnings, due in part to the non-recognition of tax benefits on losses in jurisdictions with valuation allowances. As of each reporting date, we consider new evidence, both positive and negative, that could impact our view with regards to the future realizations of deferred tax assets and the appropriateness of their related valuation allowances.

The effective income tax rate decrease in Q3-17, as compared with Q3-16, was primarily attributable to a lower percentage of income before income taxes being earned in jurisdictions where we do not maintain valuation allowances and, therefore, recognize tax expense. In addition, the recognition of previously unrecognized tax benefits, as the result of audit settlements and assessment period statute expirations, contributed to the decrease in the effective income tax rate.

The effective income tax rate increase in YTD-17, as compared with YTD-16, was primarily as a result of the following YTD-16 factors: the recognition of $2.5 million of previously unrecognized deferred tax assets which resulted from the improved performance of our FPD operations; the reversal of previously recognized tax expense of $2.4 million that was eliminated by a distribution of the earnings of a foreign subsidiary to its foreign parent; a higher percentage of income before income taxes, including an $8.8 million gain on the sale of an investment in the first quarter of fiscal year 2016, generated in jurisdictions where we previously incurred losses that, due to valuation allowances, did not result in us recognizing expense. The YTD-16 benefits were partially matched by the YTD-17 benefit realized from the recognition of previously unrecognized tax benefits, which were the result of audit settlements and assessment period statute expirations.

### Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $0.8 million in Q3-17, as compared with income of $3.4 million in Q3-16, and was $3.0 million in YTD-17, as compared with $8.2 million in YTD-16. These changes reflect changes in the financial performance of our majority-owned IC manufacturing subsidiary in Taiwan.

### Liquidity and Capital Resources

Our working capital increased to $389.3 million at July 30, 2017, as compared with $360.3 million at October 30, 2016, primarily as a result of cash generated from operating activities. Cash and cash equivalents increased to $340.6 million at July 30, 2017, as compared with $314.1 million at October 30, 2016, also primarily as a result of cash arising from operating activities. Net cash provided by operating activities was $73.8 million for the nine month period ended July 30, 2017, as compared with $91.4 million for the nine month period ended July 31, 2016, with the decrease being primarily due to the reduced net income in the current period. Net cash used in investing activities for the nine month period ended July 30, 2017, was $44.5 million, which was comprised primarily of capital expenditure payments and, to a lesser extent, a payment to acquire a business. Net cash used in financing activities of $9.9 million for the nine month period ended July 30, 2017, was comprised of repayments of long-term borrowings of $4.1 million and the payment of a dividend to the noncontrolling interest of a subsidiary of $8.3 million, which were partially offset by proceeds of $2.5 million received from exercises of employee stock options. We may use our available cash for operations, capital expenditures, debt repayments, strategic opportunities, stock repurchases or other corporate uses, any of which may be material.

As of July 30, 2017 and October 30, 2016, our total cash and cash equivalents included $179.2 million and $141.4 million, respectively, held at foreign subsidiaries. The majority of earnings of our foreign subsidiaries are considered to be indefinitely reinvested. The repatriation of these funds to the U.S. may subject these funds to U.S. federal income taxes and local country withholding tax in certain jurisdictions. Our foreign subsidiaries continue to grow through the reinvestment of earnings in additional manufacturing capacity and capability, particularly in the high-end IC and FPD areas.

In April 2017 PDMC, our majority owned IC manufacturing subsidiary in Taiwan, declared a dividend of approximately $16.6 million, approximately $8.3 million of which was paid to the third party that owns a noncontrolling interest in PDMC in the third quarter of fiscal year 2017.

In May 2016 we received cash of $93.1 million in connection with the sale of our investment in MP Mask to Micron.

In April 2016 PDMC, our majority owned IC manufacturing subsidiary in Taiwan, declared a dividend of approximately $23.8 million, approximately $11.9 million of which was paid to the third party that owns a noncontrolling interest in PDMC in the third quarter of fiscal year 2016.

In April 2016 $57.5 million of our senior convertible notes matured. We repaid $50.1 million to noteholders and issued approximately 0.7 million shares to noteholders that elected to convert their notes to common stock. The notes were exchanged at the rate of approximately 96 shares per $1,000 note principle, equivalent to a conversion rate of $10.37 per share.

Our credit facility, which expires in December 2018, has a $50 million limit with an expansion capacity to $75 million, and is secured by substantially all of our assets located in the United States and common stock we own in certain of our foreign subsidiaries. The credit facility is subject to a minimum interest coverage ratio, total leverage ratio and minimum unrestricted cash balance financial covenants, all of which we were in compliance with at July 30, 2017. We had no outstanding borrowings against the credit facility at July 30, 2017, and $50 million was available for borrowing. The interest rate on the credit facility (2.49% at July 30, 2017) is based on our total leverage ratio at LIBOR plus a spread, as defined in the credit facility. In May 2017 the credit facility was amended primarily for our new joint venture and FPD manufacturing facility in China. See Note 15 of the condensed consolidated financial statements for further discussion of our new joint venture in China and our expansion of FPD manufacturing into China.

As of July 30, 2017, we had capital equipment commitments outstanding of approximately $60 million. We believe that our currently available resources, together with our capacity for growth, and access to equity and other financing sources, will be sufficient to satisfy our currently planned capital expenditures, as well as our anticipated working capital requirements for the next twelve months. However, we cannot assure that additional sources of financing would be available to us on commercially favorable terms should our capital requirements exceed cash available from operations, existing cash, and cash available under our credit facility.

Our liquidity is highly dependent on our sales volume, cash conversion cycle, and the timing of our capital expenditures (which can vary significantly from period to period), as we operate in a high fixed cost environment. Depending on conditions in the semiconductor and FPD markets, our cash flows from operations and current holdings of cash may not be adequate to meet our current and long-term needs for capital expenditures, operations and debt repayments. However, we believe that our cash on hand, cash generated from our operations and cash committed under our credit facility will allow us to fund our operations through at least the next twelve months. Historically, in certain years, we have used external financing to fund these needs. Due to conditions in the credit markets, some financing instruments used by us in the past may not be currently available to us. We continue to evaluate further cost reduction initiatives. However, we cannot assure that additional sources of financing would be available to us on commercially favorable terms, should our cash requirements exceed cash available from operations, existing cash, and cash available under our credit facility.

### Off-Balance Sheet Arrangements

In April 2014 we acquired a 50.01% controlling interest of PDMC, our IC manufacturing facility located in Taiwan. Under the PDMC joint venture operating agreement the shareholders of PDMC may be requested to make additional contributions to PDMC. In the event that PDMC requests additional capital from its shareholders, the Company may, in order to maintain a 50.01% ownership interest, be required to make such contributions to PDMC. The PDMC operating agreement limits the amount of contributions that may be requested during both PDMC’s first four years and during any individual year within those first four years. As of July 30, 2017, we had not been requested to make any additional capital contributions to PDMC.

We lease certain office facilities and equipment under operating leases that may require us to pay taxes, insurance and maintenance expenses related to the properties. Certain of these leases contain renewal or purchase options exercisable at the end of the lease terms.

### Business Outlook

A majority of our revenue growth is expected to continue to come from the Asian region, predominantly in China. In response to this expectation, we agreed to enter into a joint venture that will complete the construction of an IC research and development and manufacturing facility in Xiamen, China, in late 2018. Production is anticipated to begin at this facility in early 2019. In addition, in August 2017, we announced our plan to construct an FPD manufacturing facility in Hefei, China, in which production is anticipated to begin in early 2019. Please refer to Note 15 of our condensed consolidated financial statements for additional information on these undertakings.

We continue to assess our global manufacturing strategy and monitor our sales volume and related cash flows from operations. This ongoing assessment could result in future facility closures, asset redeployments, impairments of intangible or long-lived assets, workforce reductions, or increasing our manufacturing capacity, all of which would be based on market conditions and customer requirements.

Our future results of operations and the other forward-looking statements contained in this filing involve a number of risks and uncertainties. While various risks and uncertainties were discussed in Part1, Item 1A in our Annual Report on Form 10-K for the year ended October 30, 2016, a number of other unforeseen factors could cause actual results to differ materially from our expectations.

### Effect of Recent Accounting Pronouncements

See “Item 1. Condensed Consolidated Financial Statements– Notes to Condensed Consolidated Financial Statements – Note 16 – Recent Accounting Pronouncements” for recent accounting pronouncements that may affect our financial reporting.

## Market risk

As filed, 2,439 characters.

### Foreign Currency Exchange Rate Risk

We conduct business in several major international currencies through our worldwide operations and our financial performance may be affected by fluctuations in the exchange rates of these currencies. Changes in exchange rates can positively or negatively affect our sales, operating margins, assets, liabilities, and equity. The functional currencies of our Asian subsidiaries are the South Korean won, the New Taiwan dollar, and the Singapore dollar. The functional currencies of our European subsidiaries are the British pound and the euro. In addition, we have transactions and balances in Japanese yen and, as a result of our announced investments in China, we will have transactions in the Chinese renminbi.

We attempt to minimize our risk of foreign currency transaction losses by producing our products in the same country in which the products are sold (thereby generating revenues and incurring expenses in the same currency), and by managing our working capital. However, in some instances, we sell products in a currency other than the functional currency of the country where it was produced, or purchase products in a currency that differs from the functional currency of the manufacturing facility. There can be no assurance that this approach will continue to be successful, especially in the event of a significant adverse movement in the value of any foreign currency against the U.S. dollar, the New Taiwan dollar or the South Korean won.

Our primary net foreign currency exposures as of July 30, 2017, included the South Korean won, the Japanese yen, the New Taiwan dollar, the Singapore dollar, the British pound and the euro. As of July 30, 2017, a 10% adverse movement in the value of these currencies against the functional currencies of our foreign subsidiaries would have resulted in a net unrealized pre-tax loss of $10.9 million. We do not believe that a 10% change in the exchange rates of other non-US dollar currencies would have a material effect on our consolidated financial position, results of operations, or cash flows in the three or nine month periods ended July 30, 2017.

### Interest Rate Risk

At July 30, 2017, we did not have any variable rate borrowings. A 10% change in interest rates would not have had a material effect on our consolidated financial position, results of operations, or cash flows in the three or nine month periods ended July 30, 2017.

## Controls and procedures

As filed, 1,925 characters.

### Evaluation of Disclosure Controls and Procedures

We have established and currently maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), designed to provide reasonable assurance that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management, including our chief executive officer (who is the Company’s principal executive officer and principal financial officer), to allow for timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, under the supervision and with the participation of our chief executive officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation our chief executive officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during our third quarter of fiscal year 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 155 characters.

There have been no material changes to risks relating to our business as disclosed in Part 1, Item 1A of our Form 10-K for the year ended October 30, 2016.

Filed Sep 8, 2017.
Source: SEC EDGAR, the filing index for accession 0001140361-17-034757. Last ingested by Listed: Nov 15, 2026, 01:00 ET. No prices; not investment advice.
